PharmD Info

A forum for Indian Pharmacy Professionals

Important: Register today to have the complete access on this forum --- Register Here
Share your Pharmacy College Newsletters or any other pharmacy relevant workshop,seminar and conference invitations on this forum.We are happy to be a media partner for your institutional programs and events. e.g. Newsletters,Pharma News, Seminars and Conferences.
Forum rules: Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
Nestlé Health Science announced that it has invested $65 million in Seres Health, a start-up based in Cambridge, Mass., that focuses on restoring the “microbiome” — the host of microorganisms that provide vital functions for humans. The company’s current focus includes treatments for infectious diseases as well as metabolic and inflammatory illnesses.

The investment in Seres Health is one of several steps Nestlé Health Science plans to take as its seeks to advance nutrition related to health care. The business would also announce that it has set up a partnership with Flagship Ventures, a venture capital firm based in Boston, to help incubate start-ups in the nutritional therapy field.

Both announcements highlight the growing ambitions of Nestlé Health Science, which was set up to help the Swiss conglomerate expand its offerings that effectively bridge the fields of nutrition and health care. It has struck deals like the acquisition of Prometheus Laboratories, which focuses on personalized patient treatments for certain kinds of diseases like irritable bowel syndrome.

“There are some specific diseases where we know nutrition plays a very important role,” Greg Behar, Nestlé Health Science’s chief executive, said.

But that mission can be much broader, according to Mr. Behar. That explains the interest in Seres Health, which has one treatment to prevent a type of microbiome infection in Phase 3, or later stage, clinical trials at the moment. Ultimately, he added, the idea is to find different ways to treat certain types of diseases through the manipulation of the body’s microbial organisms instead of through traditional drugs.
Similar Topics
Topics Statistics Last post
IQVIA, Hiring Life science Fresher Graduates
by Admin  - 07 Jun 2018, 11:40  - In: B Pharm Jobs
0 Replies 
by Admin
07 Jun 2018, 11:40
0 Replies 
by Admin
17 Dec 2018, 16:49
0 Replies 
by Admin
05 Oct 2018, 09:57
0 Replies 
by Krishna K
26 Dec 2017, 12:51
1 Replies 
by Admin
26 Jul 2018, 12:06


PROJECT OBJECTIVE: Compilation of Profiles of Phar[…]

Dear all, We would like to know your channel for c[…]

Top 20 Indian PCD Pharmaceutical Companies

Your search for the top 20 Indian PCD pharmaceuti[…]

BCMAS certification after PharmD

Good news for all PharmD graduates looking Medical[…]